Phathom Pharmaceuticals to Report Second Quarter 2025 Financial Results and Provide Business Update on Thursday, August 7, 2025
Phathom Pharmaceuticals (NASDAQ: PHAT), a biopharmaceutical company specializing in gastrointestinal disease treatments, will host a webcast on August 7, 2025, at 8:00 am EDT to discuss Q2 2025 financial results and provide a business update.
The company markets VOQUEZNA® (vonoprazan) tablets in the US for heartburn relief and GERD treatment, along with VOQUEZNA® TRIPLE PAK® and VOQUEZNA® DUAL PAK® for H. pylori infection treatment. The webcast will be accessible through Phathom's investor relations website, with a recording available for 90 days following the event.
Phathom Pharmaceuticals (NASDAQ: PHAT), un'azienda biofarmaceutica specializzata in trattamenti per le malattie gastrointestinali, terrà una webcast il 7 agosto 2025 alle 8:00 EDT per discutere i risultati finanziari del secondo trimestre 2025 e fornire un aggiornamento sull'attività aziendale.
L'azienda commercializza negli Stati Uniti le compresse VOQUEZNA® (vonoprazan) per il sollievo dal bruciore di stomaco e il trattamento del reflusso gastroesofageo (GERD), insieme a VOQUEZNA® TRIPLE PAK® e VOQUEZNA® DUAL PAK® per il trattamento dell'infezione da H. pylori. La webcast sarà accessibile tramite il sito web delle relazioni con gli investitori di Phathom e una registrazione sarà disponibile per 90 giorni dopo l'evento.
Phathom Pharmaceuticals (NASDAQ: PHAT), una compañía biofarmacéutica especializada en tratamientos para enfermedades gastrointestinales, realizará una transmisión en línea el 7 de agosto de 2025 a las 8:00 am EDT para discutir los resultados financieros del segundo trimestre de 2025 y ofrecer una actualización sobre el negocio.
La empresa comercializa en EE. UU. las tabletas VOQUEZNA® (vonoprazan) para el alivio de la acidez y el tratamiento de la enfermedad por reflujo gastroesofágico (ERGE), junto con VOQUEZNA® TRIPLE PAK® y VOQUEZNA® DUAL PAK® para el tratamiento de la infección por H. pylori. La transmisión estará disponible a través del sitio web de relaciones con inversionistas de Phathom, y la grabación podrá consultarse durante 90 días después del evento.
Phathom Pharmaceuticals (NASDAQ: PHAT)는 위장 질환 치료제를 전문으로 하는 바이오제약 회사로, 2025년 8월 7일 오전 8시 EDT에 2025년 2분기 재무 실적 및 사업 업데이트를 논의하는 웹캐스트를 개최합니다.
이 회사는 미국에서 속쓰림 완화 및 위식도 역류 질환(GERD) 치료를 위한 VOQUEZNA® (vonoprazan) 정제와 함께, H. pylori 감염 치료용 VOQUEZNA® TRIPLE PAK® 및 VOQUEZNA® DUAL PAK®를 판매하고 있습니다. 웹캐스트는 Phathom 투자자 관계 웹사이트를 통해 접속할 수 있으며, 행사 후 90일간 녹화본이 제공됩니다.
Phathom Pharmaceuticals (NASDAQ : PHAT), une entreprise biopharmaceutique spécialisée dans les traitements des maladies gastro-intestinales, organisera une webdiffusion le 7 août 2025 à 8h00 EDT pour présenter les résultats financiers du deuxième trimestre 2025 et fournir une mise à jour sur ses activités.
L'entreprise commercialise aux États-Unis les comprimés VOQUEZNA® (vonoprazan) pour le soulagement des brûlures d'estomac et le traitement du reflux gastro-œsophagien (RGO), ainsi que VOQUEZNA® TRIPLE PAK® et VOQUEZNA® DUAL PAK® pour le traitement de l'infection à H. pylori. La webdiffusion sera accessible via le site des relations investisseurs de Phathom, avec un enregistrement disponible pendant 90 jours après l'événement.
Phathom Pharmaceuticals (NASDAQ: PHAT), ein biopharmazeutisches Unternehmen, das sich auf Behandlungen von Magen-Darm-Erkrankungen spezialisiert hat, wird am 7. August 2025 um 8:00 Uhr EDT eine Webcast veranstalten, um die Finanzergebnisse des zweiten Quartals 2025 zu besprechen und ein Geschäftsupdate zu geben.
Das Unternehmen vertreibt in den USA VOQUEZNA® (Vonoprazan) Tabletten zur Linderung von Sodbrennen und Behandlung von GERD sowie VOQUEZNA® TRIPLE PAK® und VOQUEZNA® DUAL PAK® zur Behandlung von H.-pylori-Infektionen. Der Webcast ist über die Investor-Relations-Website von Phathom zugänglich, und eine Aufzeichnung wird 90 Tage nach der Veranstaltung verfügbar sein.
- None.
- None.
- Management to host conference call on Thursday, August 7, 2025, at 8:00 am EDT
FLORHAM PARK, N.J., July 28, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced that it will host a live webcast at 8:00 am EDT on Thursday, August 7, 2025, to report its second quarter 2025 financial results and provide a business update.
A live webcast and additional information about the presentation can be accessed on the Events & Presentations section of the Phathom website at https://investors.phathompharma.com/news-events/events-and-presentations. A recording will be available for 90 days following the conclusion of the meeting.
About Phathom Pharmaceuticals, Inc.
Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases. Phathom has in-licensed the exclusive rights to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB) that is currently marketed in the United States as VOQUEZNA® (vonoprazan) tablets for the relief of heartburn associated with Non-Erosive GERD in adults, the healing and maintenance of healing of Erosive GERD in adults and relief of associated heartburn, in addition to VOQUEZNA® TRIPLE PAK® (vonoprazan tablets, amoxicillin capsules, clarithromycin tablets) and VOQUEZNA® DUAL PAK® (vonoprazan tablets, amoxicillin capsules) for the treatment of H. pylori infection in adults. For more information about Phathom, visit the company’s website at www.phathompharma.com and follow on LinkedIn and X.
MEDIA CONTACT
Nick Benedetto
1-877-742-8466
media@phathompharma.com
INVESTOR CONTACT
Eric Sciorilli
1-877-742-8466
ir@phathompharma.com
© 2025 Phathom Pharmaceuticals. All rights reserved. VOQUEZNA, VOQUEZNA DUAL PAK, VOQUEZNA TRIPLE PAK, Phathom Pharmaceuticals, and their respective logos are registered trademarks of Phathom Pharmaceuticals, Inc.
FAQ
When will Phathom Pharmaceuticals (PHAT) report Q2 2025 earnings?
How can investors access Phathom Pharmaceuticals' Q2 2025 earnings webcast?
What products does Phathom Pharmaceuticals (PHAT) currently market?
What is Phathom Pharmaceuticals' main business focus?
